Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 13Thoracic 2Dermatologic 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 555Triple Negative Breast Neoplasms 94Inflammatory Breast Neoplasms 38Breast Neoplasms, Male 31Neoplasm Metastasis 27Ovarian Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Melanoma 21Pancreatic Neoplasms 14Neoplasms 14Colorectal Neoplasms 13Carcinoma, Renal Cell 12Stomach Neoplasms 11Multiple Myeloma 10Lung Neoplasms 10Carcinoma, Ovarian Epithelial 9Carcinoma, Hepatocellular 9Lymphoma, Non-Hodgkin 8Sarcoma 7Lymphoma, Follicular 7Lymphoma 7Carcinoma, Ductal, Breast 7Recurrence 6Neutropenia 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid, Acute 6Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

pembrolizumab 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma, Myxoid × Cyclophosphamide × Breast × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡